Back to top
more

Pfizer (PFE)

(Real Time Quote from BATS)

$29.72 USD

29.72
18,682,798

+0.22 (0.75%)

Updated Jul 17, 2024 12:12 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (163 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

J&J (JNJ) Q1 Earnings Beat Estimates, Pharma Sales Slow Down

by Zacks Equity Research

Johnson & Johnson (JNJ) reported mixed first quarter results, with earnings beating expectations while sales missing the same.

    Arpita Dutt headshot

    Did Pharma & Biotech M&As Pick Pace in Q1?

    by Arpita Dutt

    Post-election, hopes surged that there would be an increase in M&A activity in the pharma and biotech sector in 2017.

      Roche's Hemophilia A Drug Positive in Second Phase III Study

      by Zacks Equity Research

      Roche Holding AG's (RHHBY) unit, Genentech, announced positive interim results from the Phase III HAVEN 2 study evaluating its pipeline candidate emicizumab prophylaxis.

        Arpita Dutt headshot

        5 Drug Stocks That Could Be Big Winners this Earnings Season

        by Arpita Dutt

        Here is a look at five companies including Pfizer (PFE) that sport a favorable Zacks Rank and have a positive earnings ESP.

          Roche Launches Antibody Test to Diagnose Prostate Cancer

          by Zacks Equity Research

          Roche Holding AG (RHHBY) announced that it has launched the anti-p504s (SP116) Rabbit Monoclonal Primary Antibody for prostate cancer diagnosis on a world wise basis.

            J&J (JNJ) to Kick Off Pharma Q1 Earnings: Will it Beat?

            by Zacks Equity Research

            We expect Johnson & Johnson (JNJ), a healthcare bellwether, to beat expectations when it reports first-quarter 2017 results on Apr 18, before the opening bell.

              Aerie Reports Positive Data on Ophthalmic Drug Rhopressa

              by Zacks Equity Research

              Aerie Pharmaceuticals, Inc. (AERI) reported encouraging six-month top-line safety and efficacy results from the phase III trial, ROCKET 4, on lead product candidate Rhopressa.

                Roche's Lung Cancer Drug Alecensa Meets Primary Endpoint

                by Zacks Equity Research

                Roche (RHHBY) announced that the global, randomized phase III study, ALEX, on lung cancer drug Alecensa met its primary endpoint as an initial (first-line) treatment.

                  Swarup Gupta headshot

                  Dow 30 Stock Roundup: Boeing Bags Air Force Orders, DuPont to Sell Part of Crop Protection Biz

                  by Swarup Gupta

                  The Dow experienced a relatively quiet week as investors eagerly awaited the outcome of the Trump Xi meeting.

                    Allergan (AGN) Presents Mixed Depression Data on Botox

                    by Zacks Equity Research

                    Allergan plc (AGN) announced mixed top-line data from a mid-stage study evaluating its key drug Botox for the treatment of major depressive disorder (MDD).

                      Paratek (PRTK) Stock Continues to Rise on Positive Results

                      by Zacks Equity Research

                      Paratek Pharmaceuticals, Inc.'s (PRTK) shares are up more than 22% since it announced positive results from a phase III study of its lead pipeline candidate

                        Roche Announces Positive Data on Lung Cancer Drug Alecensa

                        by Zacks Equity Research

                        Roche Holdings AG (RHHBY) recently announced encouraging results from the phase III study, ALUR on lung cancer drug Alecensa.

                          Madeleine Johnson headshot

                          Mylan's EpiPen Recall Expanded to U.S.

                          by Madeleine Johnson

                          On Monday, Mylan NV???s (MYL) manufacturing partner Meridian Medical Technologies announced that it will expand its voluntary recall of the EpiPen to the United States after discussing with the Food and Drug Administration (FDA).

                            Pfizer Gets Regular Approval for Breast Cancer Drug Ibrance

                            by Zacks Equity Research

                            Pfizer, Inc. (PFE) announced that its supplemental new drug application (sNDA) to convert accelerated approval for Ibrance to regular approval has been approved by the FDA.

                              Swarup Gupta headshot

                              Dow 30 Stock Roundup: Apple Buys Workflow, J&J Wins European Label Expansion

                              by Swarup Gupta

                              The Dow experienced a mixed week, with most of its gains coming from encouraging economic releases.

                                AstraZeneca's (AZN) Lynparza NDA Accepted for Review by FDA

                                by Zacks Equity Research

                                AstraZeneca plc (AZN) announced that the FDA has accepted the new drug application (NDA) for Lynparza (300mg twice daily) for the maintenance treatment of patients suffering from platinum sensitive relapsed ovarian cancer with the germline BRCA mutation

                                  Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in Europe

                                  by Zacks Equity Research

                                  Pfizer, Inc.'s (PFE) rheumatoid arthritis (RA) drug, Xeljanz has received marketing approval in Europe.

                                    Eric Dutram headshot

                                    The 'Fearless Girl' Statue Isn't a Symbol, It Is an Advertisement

                                    by Eric Dutram

                                    The Fearless Girl statue has taken New York City by storm. However, this statue, which is facing down the Charging Bull, is actually an ad.

                                      Merck's Ketruda Gets Positive CHMP Opinion for Lymphoma

                                      by Zacks Equity Research

                                      Merck & Co., Inc. (MRK) recently announced that its anti-PD-1 therapy, Keytruda, has received positive opinion from CHMP for the treatment of patients with relapsed or refractory classical hodgkin lymphoma (cHL).

                                        Amgen's (AMGN) Humira Biosimilar Receives Approval in EU

                                        by Zacks Equity Research

                                        Amgen, Inc. (AMGN) announced that its biosimilar version of AbbVie Inc.'s (ABBV) rheumatoid arthritis (RA) drug Humira has been approved by the European Commission (EC).

                                          Pfizer's Immunotherapy for Skin Cancer Gets FDA Approval

                                          by Zacks Equity Research

                                          Pfizer, Inc. (PFE) and German partner Merck KGaA's investigational cancer treatment, avelumab, was approved by the FDA for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive form of skin cancer.

                                            Arpita Dutt headshot

                                            Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved

                                            by Arpita Dutt

                                            This week's highlights include rumors regarding Sanofi (SNY) acquiring Flexion, accelerated FDA approval for a Pfizer/Merck KGaA drug and drug pricing.

                                              Catalyst Pharma (CPRX) Focused on U.S. Approval for Firdapse

                                              by Zacks Equity Research

                                              We issued an updated research report on Catalyst Pharmaceuticals, Inc. (CPRX) on Mar 22.

                                                Nektar's Pain Drug Positive in Phase III Study; Shares Gain

                                                by Zacks Equity Research

                                                Nektar Therapeutics??? (NKTR) shares surged 42.6% after the company announced positive results from a phase III efficacy study evaluating its investigational candidate, NKTR-181, in patients with moderate to severe chronic low back pain.

                                                  Is Pfizer (PFE) a Great Stock for Value Investors?

                                                  by Zacks Equity Research

                                                  Let's see if Pfizer Inc. (PFE) stock is a good choice for value-oriented investors right now from multiple angles.